This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brichory, F. Articles by Hanash, S. Search for Related Content PubMed PubMed Citation Articles by Brichory, F. Articles by Hanash, S.

Proteomics-based Identification of Protein Gene Product 9.5 as a Tumor Antigen That Induces a Humoral Immune Response in Lung Cancer

Departments of Pediatrics [F. B., F. L. N., S. H.], Pathology [T. G.], and Surgery [D. B.], University of Michigan, Ann Arbor, Michigan 48109

We used a proteomic approach to identify proteins that commonly induce an antibody response in lung cancer. Sera from 64 newly diagnosed patients with lung cancer, 99 patients with other types of cancer, and 71 noncancer controls were analyzed for antibody-based reactivity against lung adenocarcinoma proteins resolved by two-dimensional PAGE. Unlike controls, autoantibodies against a protein identified by mass spectrometry as protein gene product 9.5 (PGP 9.5) were detected in sera from 9 of 64 patients with lung cancer. Circulating PGP 9.5 antigen was detected in sera from two additional patients with lung cancer, without detectable PGP 9.5 autoantibodies. PGP 9.5 is a neurospecific polypeptide previously proposed as a marker for non-small cell lung cancer, based on its expression in tumor tissue. Using A549 lung adenocarcinoma cell line, we have demonstrated that PGP 9.5 was present at the cell surface, as well as secreted. Thus, the findings of PGP 9.5 antigen and/or antibodies in serum of patients with lung cancer suggest that PGP 9.5 may have utility in lung cancer screening and diagnosis.

This article has been cited by other articles:

				J. Qiu, G. Choi, L. Li, H. Wang, S. J. Pitteri, S. R. Pereira-Faca, A. L. Krasnoselsky, T. W. Randolph, G. S. Omenn, C. Edelstein, et al. Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera J. Clin. Oncol., November 1, 2008; 26(31): 5060 - 5066. [Abstract] [Full Text] [PDF]

				T. Plavina, M. Hincapie, E. Wakshull, M. Subramanyam, and W. S. Hancock Increased Plasma Concentrations of Cytoskeletal and Ca2+-Binding Proteins and Their Peptides in Psoriasis Patients Clin. Chem., November 1, 2008; 54(11): 1805 - 1814. [Abstract] [Full Text] [PDF]

				P. M. Karamessinis, A. Malamitsi-Puchner, T. Boutsikou, M. Makridakis, K. Vougas, M. Fountoulakis, A. Vlahou, and G. Chrousos Marked Defects in the Expression and Glycosylation of {alpha}2-HS Glycoprotein/Fetuin-A in Plasma from Neonates with Intrauterine Growth Restriction: Proteomics Screening and Potential Clinical Implications Mol. Cell. Proteomics, March 1, 2008; 7(3): 591 - 599. [Abstract] [Full Text] [PDF]

				G. Sarkissian, P. Fergelot, P.-J. Lamy, J.-J. Patard, S. Culine, P. Jouin, N. Rioux-Leclercq, and B. Darbouret Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis Clin. Chem., March 1, 2008; 54(3): 574 - 581. [Abstract] [Full Text] [PDF]

				J. Madoz-Gurpide, R. Kuick, H. Wang, D. E. Misek, and S. M. Hanash Integral Protein Microarrays for the Identification of Lung Cancer Antigens in Sera That Induce a Humoral Immune Response Mol. Cell. Proteomics, February 1, 2008; 7(2): 268 - 281. [Abstract] [Full Text] [PDF]

				S. R. Pereira-Faca, R. Kuick, E. Puravs, Q. Zhang, A. L. Krasnoselsky, D. Phanstiel, J. Qiu, D. E. Misek, R. Hinderer, M. Tammemagi, et al. Identification of 14-3-3{theta} as an Antigen that Induces a Humoral Response in Lung Cancer Cancer Res., December 15, 2007; 67(24): 12000 - 12006. [Abstract] [Full Text] [PDF]

				M. Caron, G. Choquet-Kastylevsky, and R. Joubert-Caron Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery Mol. Cell. Proteomics, July 1, 2007; 6(7): 1115 - 1122. [Abstract] [Full Text] [PDF]

				B. Seliger, A. Fedorushchenko, W. Brenner, A. Ackermann, D. Atkins, S. Hanash, and R. Lichtenfels Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1] Clin. Cancer Res., January 1, 2007; 13(1): 27 - 37. [Abstract] [Full Text] [PDF]

				Y. Fujita, T. Nakanishi, M. Hiramatsu, H. Mabuchi, Y. Miyamoto, A. Miyamoto, A. Shimizu, and N. Tanigawa Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma. Clin. Cancer Res., November 1, 2006; 12(21): 6415 - 6420. [Abstract] [Full Text] [PDF]

				M. Chatterjee, S. Mohapatra, A. Ionan, G. Bawa, R. Ali-Fehmi, X. Wang, J. Nowak, B. Ye, F. A. Nahhas, K. Lu, et al. Diagnostic Markers of Ovarian Cancer by High-Throughput Antigen Cloning and Detection on Arrays Cancer Res., January 15, 2006; 66(2): 1181 - 1190. [Abstract] [Full Text] [PDF]

				K. Yoshiura, T. Nakaoka, T. Nishishita, K. Sato, A. Yamamoto, S. Shimada, T. Saida, Y. Kawakami, T. A. Takahashi, H. Fukuda, et al. Carbonic Anhydrase II Is a Tumor Vessel Endothelium-Associated Antigen Targeted by Dendritic Cell Therapy Clin. Cancer Res., November 15, 2005; 11(22): 8201 - 8207. [Abstract] [Full Text] [PDF]

				L. Zhong, G. E. Hidalgo, A. J. Stromberg, N. H. Khattar, J. R. Jett, and E. A. Hirschowitz Using Protein Microarray as a Diagnostic Assay for Non-Small Cell Lung Cancer Am. J. Respir. Crit. Care Med., November 15, 2005; 172(10): 1308 - 1314. [Abstract] [Full Text] [PDF]

				S. K. Pedersen, A. J. Sloane, S. S. Prasad, L. T. Sebastian, R. A. Lindner, M. Hsu, M. Robinson, P. T. Bye, R. P. Weinberger, and J. L. Harry An Immunoproteomic Approach for Identification of Clinical Biomarkers for Monitoring Disease: Application to Cystic Fibrosis Mol. Cell. Proteomics, August 1, 2005; 4(8): 1052 - 1060. [Abstract] [Full Text] [PDF]

				M. Meyerson and D. Carbone Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted Therapy J. Clin. Oncol., May 10, 2005; 23(14): 3219 - 3226. [Abstract] [Full Text] [PDF]

				S. Skvortsov, B. Sarg, J. Loeffler-Ragg, I. Skvortsova, H. Lindner, H. Werner Ott, P. Lukas, K. Illmensee, and H. Zwierzina Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment Mol. Cancer Ther., December 1, 2004; 3(12): 1551 - 1558. [Abstract] [Full Text] [PDF]

				H. Ovaa, B. M. Kessler, U. Rolen, P. J. Galardy, H. L. Ploegh, and M. G. Masucci Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells PNAS, February 24, 2004; 101(8): 2253 - 2258. [Abstract] [Full Text] [PDF]

				P. J. Adam, J. Berry, J. A. Loader, K. L. Tyson, G. Craggs, P. Smith, J. De Belin, G. Steers, F. Pezzella, K. F. Sachsenmeir, et al. Arylamine N-Acetyltransferase-1 Is Highly Expressed in Breast Cancers and Conveys Enhanced Growth and Resistance to Etoposide in Vitro Mol. Cancer Res., September 1, 2003; 1(11): 826 - 835. [Abstract] [Full Text] [PDF]

				G. Chen, T. G. Gharib, C.-C. Huang, D. G. Thomas, K. A. Shedden, J. M. G. Taylor, S. L. R. Kardia, D. E. Misek, T. J. Giordano, M. D. Iannettoni, et al. Proteomic Analysis of Lung Adenocarcinoma: Identification of a Highly Expressed Set of Proteins in Tumors Clin. Cancer Res., July 1, 2002; 8(7): 2298 - 2305. [Abstract] [Full Text] [PDF]